

1 Laying the Foundation for *iCANmeditate*: A mixed methods study protocol for understanding  
2 patient and oncologist perspectives on meditation  
3  
4  
5  
6

7 Yasmin Lalani<sup>1</sup>, Alexandra Godinho<sup>1</sup>, Kirsten Ellison<sup>1</sup>, Krutika Joshi<sup>1</sup>, Aisling Curtin Wach<sup>1</sup>,  
8 Punam Rana<sup>2</sup>, Pete Wegier<sup>1,3</sup>  
9

10  
11 <sup>1</sup>Humber River Health Research Institute, Humber River Health, Toronto, Ontario, Canada  
12

13 <sup>2</sup>Humber River Health, Toronto, Ontario, Canada  
14

15 <sup>3</sup>Humber River Health Research Institute, Humber River Health, Toronto, Ontario, Canada;  
16 Department of Family and Community Medicine, Toronto, Ontario, Canada; Institute of Health  
17 Policy, Management and Evaluation, Toronto, Ontario, Canada.  
18

19  
20 \*Corresponding author  
21

22 Email: [ylalani@hrh.ca](mailto:ylalani@hrh.ca)  
23  
24  
25

26  
27

## 28 **Abstract**

29

## 30 **Background**

31

32 People with cancer experience heightened levels of stress and anxiety, including psychological  
33 or physical. In recent years, digitally delivered complimentary therapies, such as meditation,  
34 have gained attention in cancer research and advocacy communities for improving quality of life.  
35 However, most digital meditation resources are commercially available and are not tailored to  
36 the unique needs of cancer patients (addressing fears of recurrence). As such, this study lays the  
37 foundation to co-design a publicly available digital meditation program called *iCANmeditate* that  
38 contains cancer-specific meditation content.

## 39 **Aims**

40

41 To understand: (1) cancer patients' perceptions and practices of meditation, as well as their needs  
42 in addressing the stress that accompanies their cancer diagnosis and (2) current knowledge of  
43 meditation and prescribing trends amongst oncologists in Canada.

## 44 **Methods and analysis**

45

46 A mixed-methods design comprised of online patient and oncologist surveys and a series of  
47 patient focus groups will be used. Survey data analysis will use multivariate logistic regressions  
48 to examine predictors of: (1) interest in using a meditation app among patients and (2)  
49 prescribing meditation among oncologists. Patient focus groups will gather insights about the

50 contexts of daily living where meditation would be most beneficial for people with cancer; this  
51 data will be analyzed thematically.

## 52 **Discussion**

53  
54 The results of this study will inform iterative co-design workshops with cancer patients to build  
55 the digital meditation program *iCANmeditate*; focus group results will be used to develop  
56 vignettes or “personas” that will supply the initial stimulus material for the iterative co-design  
57 workshops. Once the program has been finalized in partnership with cancer patient participants,  
58 a usability and pilot study will follow to test the functionality and efficacy of the tool. Results  
59 from the oncologist survey will form the basis of knowledge mobilization efforts to facilitate  
60 clinical buy-in and awareness of the benefits of meditation to cancer patients.

## 61 **Introduction**

62  
63 Most people with cancer experience heightened levels of stress, which can continue post-  
64 recovery for many.(1, 2) This stress can take several forms including psychological and physical  
65 stress, as well as stress that accompanies patients’ fears of uncertainty about the future.(3) Such  
66 stressors have been associated with changes in immune system function, negative mental health  
67 outcomes, and reduced quality of life.(4) Moreover, some of the core symptoms that have been  
68 identified as requiring improved management strategies among cancer patients go hand-in-hand  
69 with stress such as: anxiety, depression, fatigue, pain, and insomnia.(5) Although several  
70 medications can assist with the management of these symptoms, cancer patients have  
71 increasingly become interested in using complementary therapies due to their perceived safety,  
72 potential for reducing side effects, and improving overall well-being.(6, 7)

73           One complementary therapy that has shown positive outcomes for patients to manage  
74 their cancer-related symptoms is meditation.(8, 9) Meditation is a mind-body practice that  
75 involves focusing one’s attention on the present to achieve mental clarity. As a whole,  
76 meditation can refer to several different techniques (e.g., body-centered, mindful, or  
77 contemplative) and relies on different bodily mechanisms to focus one’s attention (e.g., breath,  
78 sounds, visualizations).(10) With its roots in Eastern spiritual traditions, it has gained widespread  
79 appeal in healthcare and clinical practice guidelines as an evidence-based therapy for improving  
80 mental health (i.e., anxiety, depression, psychological distress), physical health (e.g., sleep,  
81 fatigue, pain, feeling sick), and overall quality of life in those affected by cancer.(11, 12)

82           The uptake of meditation in cancer populations is also rising, marked by surveys  
83 demonstrating over one third of patients use it as a form of complementary therapy,(6) and via  
84 the growing number of studies examining its efficacy across different types and stages of  
85 cancer.(13-17) Moreover, a general shift towards offering meditation as a digital resource has  
86 been observed within the last decade, as compared to traditional in-person sessions. Many  
87 scholars argue that online or smartphone-based meditation apps offer cancer patients greater  
88 flexibility and access to care, by removing some of the reported challenges of attending face-to-  
89 face classes such as: lack of nearby services, competing interests for time (e.g., appointments,  
90 caregiver availability, childcare), and committing to travel and lengthy sessions when distressed  
91 and fatigued.(18-20) In addition, recent findings have also shown a preference among cancer  
92 patients for using smartphone applications to learn about support care services, particularly  
93 among younger and non-white patients thereby making digital meditation a potentially viable  
94 support service.(21)

95           Commercially available digital meditation tools have shown promise in cancer patients,  
96 with initial efficacy trials demonstrating these tools to be comparable to in-person sessions in  
97 terms of acceptability, feasibility, and positive outcomes for cancer populations.(22-24)  
98 However, despite the numerous publicly available digital meditation tools on the market (e.g.,  
99 Calm™, Headspace™) that have shown promise in cancer patients, few are tailored to the  
100 specific needs and preferences of people affected by cancer.(14, 20, 25) Indeed, findings from a  
101 recent study suggest that cancer patients would prefer to use digital meditation tools that are  
102 optimized to their needs and preferences.(8, 26) In particular, Huberty and colleagues revealed  
103 that cancer patients who used the commercially available Calm™ app for meditation, have  
104 expressed modifications to Calm™ to contain information about how to center on positive  
105 feelings, how to manage negative feelings associated with their cancer journey, and content that  
106 promotes movement-based activities.(26)

107           To address this gap and provide a publicly available solution, we propose to co-design a  
108 digital meditation tool called *iCANmeditate* that is tailored to the specific needs of cancer  
109 patients and leverages an existing hospital-based digital platform. We will be conducting this  
110 study with the guidance of one of the authors, Dr. Punam Rana who is a medical oncologist and  
111 certified meditation teacher (<https://drpunamrana.com/>). However, to accomplish this our team  
112 must first understand: (1) patient perceptions and practices of meditation as well as the needs and  
113 concerns of cancer patients' experiences with stress and coping with their diagnosis and (2)  
114 current knowledge of meditation and prescribing trends amongst oncologists. To date, only one  
115 study has examined the knowledge and perceptions of meditation among cancer patients in  
116 preparation for designing a tool.(27) Overall, this study found that while the benefits of  
117 meditation were generally understood by cancer patients, one of the main barriers to engaging

118 with meditation was a lack of perceived knowledge. In addition, these scholars found that  
119 experience with meditation use seemed to vary by gender, age, and education level, however,  
120 interest in a digital resource was highly correlated with reporting a higher level of stress.(27)  
121 Although these findings are important for understanding the characteristics of cancer patients  
122 who may be more likely to use and benefit from a digital meditation tool, this study was limited  
123 to melanoma patients and is not generalizable to all cancer types and stages.

124

## 125 **Aim of the study**

126

127 We propose to conduct a survey and in-depth focus groups on patient knowledge, prior  
128 use, and attitudes towards meditation as it relates to their experiences of stress and coping with  
129 their diagnosis. In addition, we also propose to survey Canadian oncologists on their current  
130 knowledge and attitudes towards meditation, as no study to date has been conducted in this area  
131 to our knowledge. The survey will ask oncologists about their awareness of different digital  
132 meditation resources and clinical practice guidelines, as well as current practices in prescribing  
133 meditation to their patients. As this study is exploratory in nature, no a priori hypotheses were  
134 made.

## 135 **Methods**

136

### 137 **Participants**

#### 138 **Patients**

139 Outpatients attending the Humber River Health Cancer Clinic will be invited to take part  
140 in a survey about well-being, including strategies for coping with their stress and anxiety.  
141 Eligibility criteria will consist of being 18 years of age or older, currently receiving treatment for  
142 cancer and English-speaking; for focus group participants they will have indicated on the survey  
143 that they would be interested to engage in focus groups. Individuals will not be excluded based  
144 on type or stage of cancer, however those with cognitive impairments, psychiatric illness, or are  
145 too distressed to participate as identified by clinicians will be excluded. The following types of  
146 cancer will be excluded from the sample as they are not currently treated at the clinic: head,  
147 neck, sarcoma, skin, melanoma, gynecological cancers.

148

## 149 **Oncologists**

150 Members of the Canadian Association of Medical Oncologists (CAMO) will be invited to  
151 take part in a brief online survey about their perspectives on prescribing meditation to improve  
152 quality of life in cancer patients. CAMO is comprised of over 350 members that include: medical  
153 oncologists, residents, fellow, and associates. Eligibility criteria will consist of being 18 years of  
154 age or older, having completed their fellowship, and practicing medical oncology.

## 155 **Study Design and Procedures**

### 156 **Patient Survey and Focus Groups**

157 Eligible participants will be identified through Humber River Health's Cancer Clinic  
158 outpatient treatment appointment lists, and clinical eligibility will be determined in consultation  
159 with a clinical nurse coordinator. Recruitment will take place in the cancer clinic treatment area,  
160 with research staff systematically approaching all patients in treatment bays who have not been  
161 identified by nursing staff as being on airborne precautions, significantly distressed, or

162 cognitively unable to provide consent. Patients will be invited to participate in a survey about  
163 cancer patient's well-being, including experiences of stress, anxiety, and quality of life. To  
164 ensure that patients in the clinic understand research activities are not a part of standard clinical  
165 care, posters will be placed in the cancer clinic waiting room. To reduce self-selection biases  
166 (i.e., recruiting only participants who are interested in meditation), and capture a wide range of  
167 patients' perceptions and barriers towards meditation, participants will be blinded to the purpose  
168 of the survey. Consent forms and recruitment scripts will not include any mention of meditation.  
169 Interested potential participants will be directed to an online consent form by research staff on  
170 their individual integrated bedside terminal (i.e., tablet); this is a confidential and private tablet  
171 available to each patient receiving treatment in the cancer clinic. Informed consent will include  
172 an optional consent to be contacted for future studies and anonymous data sharing (i.e., open  
173 science). To ensure consent is informed, potential participants will be provided with the  
174 opportunity to ask questions and express concerns to research staff, with teach-back strategies  
175 being used as needed.(28) Those who complete the consent form will be redirected to an online  
176 survey. Upon survey completion participants will be debriefed about the true aims of the study  
177 (i.e., to understand patient perspectives and experience with meditation in preparation of  
178 developing a digital meditation tool) and will be provided with a patient resource about  
179 meditation. If participants feel some discomfort in reflecting about their wellbeing and quality of  
180 life even after they complete the survey, there is a distress centre phone number indicated on the  
181 consent form. In addition, all participants who complete the survey will be provided with a \$5  
182 physical gift card as a token of appreciation.

183 Participants who indicate on the survey that they would be interested in using a digital  
184 meditation resource and participating in online focus groups to help develop a cancer-specific



185 meditation program will be considered for participation in virtual focus groups. Participant  
186 characteristics and experience with meditation will be used to guide the selection of participants;  
187 a maximum of 15 participants will be recruited for two independent focus groups. This will be a  
188 purposive, homogeneous sample of approximately six to eight participants per focus group, with  
189 a cancer diagnosis, and some experience with meditation. Focus groups with an overarching  
190 homogeneous composition can be desirable to create a comfortable environment for self-  
191 expression amongst participants who have a shared experience.(29, 30) Participants who are  
192 selected for participation will be emailed a consent form outlining the study in greater detail. To  
193 ensure consent is informed, participants will be encouraged to discuss questions and concerns  
194 with research staff via email or phone calls prior to consenting to participate; again teach-back  
195 strategies will be used when appropriate.(28) Those who complete the consent form will be  
196 invited to attend up to four online focus groups. All participants who engage in focus groups will  
197 be compensated with the equivalent of \$25/hour in the form of an electronic gift card (maximum  
198 compensation of \$200 if participants attend 4 focus group sessions). All focus group sessions  
199 will be video, and audio recorded as well as transcribed verbatim. The video files will be  
200 permanently deleted, and the audio files will be kept for analysis. Risks of participating in focus  
201 groups may be momentarily discomfort of talking about their cancer experiences or hearing  
202 others' experiences; if participants still feel distress after the focus group sessions, they may refer  
203 to the Distress Centres of Greater Toronto phone number indicated on the consent form as a way  
204 to seek professional help. All identifying information from audio transcripts will be removed.

## 205 **Oncologist Survey**

206 Medical oncologists who are members of CAMO will be invited to complete a survey  
207 about their perspectives and knowledge of meditation for improving quality of life in cancer

208 patients via an email survey blast. To promote recruitment efforts, up to two reminders will be  
209 sent 1-week post-initial survey email blast, and first reminder, respectively. Those who are  
210 interested in completing the survey will be directed to an electronic consent form via a link  
211 contained in the invitation email. Potential participants who complete the electronic consent will  
212 be automatically directed to the survey on their browser. Upon completion of the survey,  
213 oncologists will be provided with a meditation resource that they can view and download.  
214 Participants will be compensated with a \$5 electronic gift card.

215

## 216 **Meditation Resources**

217 All meditation resources in this study provide a plain-language overview of meditation  
218 and draw on existing meditation resources provided by the Canadian Cancer Society, the  
219 National Center for Complementary and Integrative Health, and the Memorial Sloan-Kettering  
220 Cancer Centre. All materials have been reviewed for accuracy by the clinical subject matter lead  
221 for meditation.

### 222 **Patient Meditation Resource**

223 Following the completion of the patient survey, participants will be offered a tri-fold  
224 brochure that provides a plain-language overview of what meditation is and how it has been  
225 shown to benefit cancer patients. The brochure will also provide them with a link and QR code to  
226 Dr. Punam Rana's website, where they will have access to additional resources and information.

### 227 **Oncologist Meditation Resource**

228 A one-page document will also be made available at the end of the survey to oncologists  
229 who express interest in learning more about meditation (i.e., respond "yes" to survey item asking  
230 about interest in meditation resources). This electronic pdf will provide oncologists with a plain-

231 language overview of what meditation is and how it has been shown to benefit cancer patients.  
232 The document will also provide them with references to current clinical guidelines and a list of  
233 relevant online resources and recommended patient resources.

## 234 **Measures and Qualitative Methods**

### 235 **Patient Survey Measures**

236 The survey will assess a variety of demographic characteristics that have been associated  
237 with meditation practice such as: age, sex at birth, education level, employment, and religion. In  
238 addition, clinical characteristics such as cancer diagnosis details (i.e., type, stage, date of  
239 diagnosis) and mental health outcomes will also be assessed.(31, 32)

240 *Mindfulness.* Everyday mindfulness will be measured using the Cognitive and Affective  
241 Mindfulness Scale-Revised (CAMS-R), which measures the following aspects of mindfulness:  
242 present-focused attention, awareness, and nonjudgmental acceptance of thoughts and  
243 emotions.(33) This tool has been shown to be suitable for use in meditating as well as non-  
244 meditating samples, and is commonly used in cancer patient samples to assess individual  
245 differences in dispositional mindfulness.(27) This study will use the brief 10-item version of the  
246 tool, where scores range from 10 to 40,with higher scores representing greater self-reported  
247 mindfulness.

248 *Experience With Meditation.* A series of questions have been developed by the team, in  
249 consultation with a meditation expert (Dr. Punam Rana), to assess patients' practice of  
250 meditation. In particular, participants will be asked about: type of meditation practiced (e.g.,  
251 mindful, transcendental); resources used (e.g., apps, books, websites); tools to assist in  
252 meditating (e.g., incense, mat, bells); duration and frequency of practice (months/years,  
253 daily/weekly/monthly); and changes in meditation since their cancer diagnosis (decision to

254 meditate/frequency). In addition, participants will also be asked about current interest in learning  
255 more about meditation, continuing their current practice, and the extent to which they feel their  
256 practice of meditation is helpful.

257 *Barriers to Meditation.* Perceived barriers for meditating among cancer patients who currently  
258 meditate, versus those who do not practice meditation will be assessed using the Determinants of  
259 Meditation Practice Inventory – Revised (DMPI-R).(34) This briefer version of the full  
260 DMPI,(35) is a psychometrically validated 12-item self-report tool that measures 4 subscales of  
261 barriers to meditating: low perceived benefit, perceived inadequate knowledge, perceived  
262 pragmatic barriers, and perceived socio-cultural conflict. Each subscale is comprised of 2 - 4  
263 items that are scored on a 5-point Likert-type scale, with higher scores indicating a higher  
264 perception of that perceived group of barriers.

265 *Knowledge of Meditation.* Patient knowledge of meditation will be assessed using a series of  
266 questions that gauge general perceptions of meditation. A set of 10 items have been developed  
267 by Russell et al.(27) to assess knowledge of meditation. Survey respondents are asked to rate  
268 their agreement with 10 statements (i.e., seven facts and three misconceptions that are reverse  
269 scored), using the response options 1 “Agree”, 0 “Don’t know” or -1 “Disagree. Overall, higher  
270 total scores indicate greater knowledge of meditation.

## 271 **Focus Groups**

272 The purpose of the focus groups will be to explore participants’ (1) experiences,  
273 perceptions, and preferences regarding meditation and (2) how and under what contexts their  
274 practice of meditation has (or has not) helped the cope with their cancer diagnosis. The focus  
275 group guide is structured based on focus group question route methodology; general questions  
276 will be asked first followed by more specific key questions directly related to the research topic

277 so that participants are given ample time to “warm up” and feel comfortable with one  
278 another.(36, 37)

279 The moderator of the focus groups will be a member of the research team with qualitative  
280 research expertise. Additionally, a notetaker and technical support person will be present with  
281 their cameras off. The notetaker will capture non-verbal interactions amongst participants and  
282 any other data which would add to a fuller picture of the focus group event. The technical  
283 support person will be available to troubleshoot any issues with the Zoom platform that  
284 participants may have, as well as monitor the chat function.

285 To capture the majority of themes, it is preferable to build in more than one focus  
286 group.(38) Thus, after the first focus group session, we will invite participants to return for a  
287 second, third, or fourth focus group session until data saturation has been reached. Depending on  
288 availability, we will invite the same participants to all focus groups; however, if there is a  
289 demand for focus group participation, we may conduct further focus groups with different  
290 participants from the survey participant pool.

## 291 **Oncologist Survey Measures**

292 The survey will assess demographic characteristics such as participant age and sex as  
293 well as professional practice characteristics including main place of work, years and province of  
294 practice, and area of oncology specialty. To determine current practices around recommending  
295 alternative and complementary therapies for alleviating stress and anxiety among cancer patients,  
296 participants will be asked to identify any therapies they currently recommend from a pre-  
297 specified list of the most common forms (e.g., music therapy, meditation, acupuncture); an open-  
298 ended user option will also be included to capture therapy forms not listed.

299

300 *Meditation Recommendation Practices.* To assess the proportion of survey completers who  
301 specifically recommend meditation, an additional yes/no question will be asked to those who do  
302 not select meditation from the aforementioned list (i.e., “Have you *ever* recommended  
303 meditation to your patients?”). In addition, for those who respond that they do or have  
304 recommended meditation, further questions will assess the forms of meditation that have been  
305 recommended (i.e., types of meditation vs. delivery format), and how the recommendation was  
306 made. In order to better understand how oncologists recommend meditation to their patients, an  
307 item was developed to assess the physicians’ level of engagement in providing information and  
308 resources about meditation. This item will ask “Which statement best describes how you  
309 recommend meditation to your patients?” and provide the following response options: (a) I  
310 suggest meditating to help with stress and anxiety, (b) I recommend meditation to my patients  
311 and provide them with resources to help them learn and understand how to meditate, and (c) I  
312 explain the benefits of meditation to my patients and provide them with resources to help them  
313 learn and understand how to meditate.

314 *Knowledge of Meditation.* The survey will also aim to understand oncologists’ attitudes and  
315 knowledge of meditation, by asking the same series of questions outlined for patient participants;  
316 see above.(27)

317 *Awareness of Practice Guidelines Endorsing Meditation.* The last component of the survey aims  
318 to understand oncologists’ general awareness for guidelines that currently recommend meditation  
319 to cancer patients. In 2018, the American Society for Clinical Oncology (ASCO), endorsed  
320 guidelines put forth by the Society for Integrative Oncology (SIO), recommending music  
321 therapy, meditation, stress management, and yoga for anxiety and stress reduction among breast  
322 cancer patients. Survey respondents will be presented with a partial screenshot of the practice

323 guidelines and items will be asked to assess (1) knowledge/awareness for the guidelines, (2) if  
324 their recommendations of integrative therapies changed upon release of the guidelines, and if so  
325 what therapies they started recommending to their patients, and (3) for those without awareness  
326 for the guidelines, if becoming aware of them via the survey would influence their  
327 recommendation of integrative therapies moving forward as well as which specific therapies they  
328 will begin recommending to patients.

## 329 **Data Management**

330 The electronic platform, Qualtrics, used to collect consent and participant data for both the  
331 patient and oncologist online surveys ensures research participants' privacy and confidentiality,  
332 and does not share data with third parties. Survey responses on Qualtrics are protected by  
333 Qualtrics' Web Application Firewalls and their detection system that monitors for unauthorized  
334 users. Data will not be linked from other sources and will only be used for purposes outlined in  
335 the consent documentation. Patient and oncologist digital survey data will be stored in a secure  
336 computer file and will be deleted upon the completion of the study. A Master Linking Log that  
337 contains patients' Study IDs and personal identifying information will be kept as a password  
338 protected file, accessible to the research team during the recruitment process only. Focus group  
339 audio files will be sent to a transcription service using secure file transfer; transcripts and  
340 fieldnotes will be anonymized and stored both in a locked office (if they are printed as paper  
341 copies) as well as digitally as password protected digital files. All study data (i.e., survey data  
342 /focus group transcripts) will be stored securely for at least five years on Humber River Health's  
343 encrypted cloud storage, after which the de-identified data will be deposited into Humber River  
344 Health's Institutional Repository for a period of 10 years. The de-identified data will not be sold  
345 and will only be accessible to the study team.

## 346 **Data analysis and sample size calculations**

### 347 **Patient Survey Data Analysis and Sample Calculation**

348 The primary analysis will be a prediction of who is interested in using a meditation app,  
349 applying multivariate Logistic Regression with two-sided  $p < 0.05$  as critical value. The covariates  
350 include age, anxiety level, perceived stress, and perceived mindfulness while the factors include  
351 sex and whether the patient uses alternate methods of stress management. In secondary analyses,  
352 we will use bivariate statistical analyses to identify relationships, interactions, or differences  
353 between the covariates/factors using T-tests and Spearman correlations. Based on the number of  
354 covariates/factors ( $k=6$ ), and a lower estimate of the proportion of the positive outcome variable  
355 (40%;  $v=0.4$ ), the minimum number of cases required is calculated by the formula ( $N=10k/v$ ), as  
356 determined by Peduzzi, et al.(39) This results in a calculated sample size of 150 for a meaningful  
357 logistic regression analysis.

### 358 **Patient focus group data analysis**

359 Analysis of focus groups will require a dynamic, non-linear, and iterative engagement  
360 with the following data items: transcripts, fieldnotes, selective listening of audio, photos of any  
361 activities captured during the recording of the online focus group such as: Poll Everywhere,  
362 Zoom Whiteboard notes in the chat etc. The moderator team will meet to debrief immediately  
363 after the focus group to discuss particular moments in the session that are noteworthy or that may  
364 require special attention during analysis.

365 All data forms listed above will be uploaded into NVivo 12 qualitative analysis software  
366 program as the majority of the analysis steps will be conducted in this program. To ensure that  
367 analysis is trustworthy, focus group data will be analyzed by the qualitative lead in the research



368 team. The approach to analysis will be iterative and performed in sequence; when each focus  
369 group is complete, data analysis will begin prior to the next scheduled focus group. This will  
370 allow time for theoretical sampling to take place for the subsequent focus group, in the event that  
371 a particular theme or topic requires refining. As each focus group is completed, data will be  
372 analyzed using the constant comparison method which includes (1) coding the data into small  
373 units and attaching a descriptor or ‘code’ to each unit, (2), grouping the codes into larger  
374 categories (axial coding), and (3) developing broader themes from larger categories.(40, 41)

375 The lead analyst will work with the note-taker to discuss codes and themes that are under  
376 construction during the analysis process. The purpose of these discussions is twofold: (1) to  
377 achieve consensus regarding the meanings and definitions of codes as well as resulting themes to  
378 resolving and (2) to incorporate any non-verbal communicative data from the recording as well  
379 as other dynamic moments of interaction captured via notes rather than solely the transcript. In  
380 doing so, we will eliminate as much as possible, the potential misleading interpretations of  
381 participants’ voices analyzed as words on the transcript only.

## 382 **Oncologist survey data analysis and sample calculation**

383 The primary analysis will be a prediction of who prescribes meditation using multivariate  
384 Logistic Regression with two-sided  $p < 0.05$  as critical value. The covariates include age while the  
385 factors include sex and whether alternate therapies are recommended. In secondary analyses, we  
386 will use multiple regression to determine relationships between the covariates/factors. We will  
387 also test for interactions, particularly between whether alternate therapies are recommended and  
388 who prescribes meditation. Based on the number of covariates/factors ( $k=3$ ), and a lower  
389 estimate of the proportion of the positive outcome variable (20%;  $v=0.2$ ), the minimum number  
390 of cases required is calculated by the formula ( $N=10k/v$ ), where 10 is the minimum number of

391 ‘events per variable’ as determined by Peduzzi, et al.(39) This results in a calculated sample size  
392 of 150 for a meaningful logistic regression analysis. As a result, all oncologists belonging to the  
393 Canadian Institution of Medical Oncologists (CAMO) will be given the survey.

## 394 **Discussion**

### 395 **Significance of the proposed study**

396  
397 The study outlined in this protocol aligns with recent research in healthcare interventions  
398 and delivery that empowers patients to engage with digital solutions to manage their symptoms  
399 and enhance their wellbeing.(42, 43) Cancer patients in particular experience stress, pain, and  
400 decreased quality of life as a consequence of their diagnosis; some patients would therefore  
401 benefit greatly from a digital tool for symptom management. Thus, this study responds to the  
402 most recent call for online meditation programs for cancer to be tailor-made for cancer patients  
403 as opposed to standard meditation digital applications.(8, 26)

404 This study protocol serves as the first step to address this gap; it outlines the rationale and  
405 procedures for understanding cancer patients’ perceptions and practices of meditation as well as  
406 their experiences of how meditation may have benefited them. In tandem with the quantitative  
407 and qualitative patient data, the survey results of practicing oncologists in Canada will aid in our  
408 understanding of their prescribing practices and state of meditation knowledge. Taken together,  
409 the patient and oncologist datasets will prepare the infrastructure needed for the next phase of the  
410 broader research goal—to co-design and pilot test an online meditation program called  
411 *iCANmeditate*.

412 The co-design process will be informed by vignettes generated from patient focus group  
413 data. Vignettes are fictional representations or “personas” of individuals’ experiences of the  
414 topic under study and have practical applications in healthcare in co-design or participatory

415 health research.(44) Vignettes will be presented to cancer patient participants during the  
416 development phase of this larger research program to: (1) develop content and a prototype of the  
417 online meditation tool on the hospital’s platform and (2) to test the usability of the meditation  
418 program. Co-design workshops will be run iteratively with feedback incorporated by  
419 participants until *iCANmeditate* is complete. A pilot study will follow the development of  
420 *iCANmeditate* to measure the tool’s efficacy.

## 421 **Strengths and Limitations**

422 One key strength of this study is our engagement with oncologists in Canada; there is a  
423 paucity of research that demonstrates the level of knowledge and prescribing behaviours of  
424 meditation as a complimentary integrative therapy from oncologists despite the fact that  
425 meditation is included in some clinical guidelines.(11, 45) Consequently, a long-term goal for  
426 the meditation program is to convey the value of meditation by involving oncologists so that  
427 meditation does not continue to be a “fringe” therapy with little clinical endorsement.

428 Possible limitations of this foundational study can be pinpointed. One limitation is that  
429 the patient population drawn from the hospital study site may not be representative of patients  
430 with cancer at a national or provincial level. For instance, the patient survey excludes  
431 participants whose command of English is weak and as such, survey results will only reveal data  
432 from an English-speaking group. Secondly, the hospital study site does not treat all types of  
433 cancer and thus, a comprehensive understanding of patients’ knowledge of meditation will  
434 exclude patients with head, neck, sarcoma, gynecological, skin and melanoma cancers. In a  
435 similar vein, the target population for the patient survey is patients who are actively in treatment  
436 and not patients who were recently diagnosed. Our rationale for excluding this group was to  
437 avoid adding an emotional burden to patients who may still be coming to terms with their cancer

438 diagnosis. Finally, our patient sample will not include individuals who may identify as  
439 “survivors”; the concept of survivorship in cancer is an emerging field of study and  
440 consequently, outside the scope of this investigation of cancer patients currently in treatment.

441 In conclusion, this protocol outlines the research activities required to move to our next  
442 phase of research where continuous engagement with cancer patients during the co-design phase  
443 will produce a unique and meaningful meditation program that incorporates the specific needs of  
444 people with cancer. This protocol has been approved by Veritas Independent Review Board,  
445 Tracking Number: 2023-3319-15429-4.

## 446 **Acknowledgements**

447  
448 We would like to thank the Cancer Care Clinic at Humber River Health for their continuing  
449 support of this research program.

450  
451  
452

## 453 **References**

- 454 1. Bates GE, Mostel JL, Hesdorffer M. Cancer-related anxiety. *JAMA oncology*.  
455 2017;3(7):1007-.
- 456 2. Cillessen L, Johannsen M, Speckens AEM, Zachariae R. Mindfulness-based  
457 interventions for psychological and physical health outcomes in cancer patients and survivors: A  
458 systematic review and meta-analysis of randomized controlled trials. *Psychooncology*.  
459 2019;28(12):2257-69.
- 460 3. Børøsund E, Mirkovic J, Clark MM, Ehlers SL, Andrykowski MA, Bergland A, et al. A  
461 stress management app intervention for cancer survivors: design, development, and usability  
462 testing. *JMIR formative research*. 2018;2(2):e9954.
- 463 4. Antoni MH, Dhabhar FS. The impact of psychosocial stress and stress management on  
464 immune responses in patients with cancer. *Cancer*. 2019;125(9):1417-31.
- 465 5. Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al. Recommended  
466 Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. *J Natl*  
467 *Cancer Inst*. 2014;106(7).
- 468 6. Huebner J, Prott FJ, Micke O, Muecke R, Senf B, Dennert G, et al. Online survey of  
469 cancer patients on complementary and alternative medicine. *Oncology research and treatment*.  
470 2014;37(6):304-8.
- 471 7. Tangkiatkumjai M, Boardman H, Walker D-M. Potential factors that influence usage of  
472 complementary and alternative medicine worldwide: a systematic review. *BMC Complementary*  
473 *Medicine and Therapies*. 2020;20(1):1-15.
- 474 8. Klainin-Yobas P, Hounsri K, Chng WJ, Ang NKE, Goh Y-SS. Preventing psychological  
475 symptoms among cancer survivors through a digital mindfulness psychoeducation program:  
476 Protocol of a randomized controlled trial. *medRxiv*. 2023:2023.01. 05.23284230.
- 477 9. Tacón AM. Meditation as a complementary therapy in cancer. *Family and Community*  
478 *Health*. 2003;26(1):64-73.
- 479 10. Matko K, Sedlmeier P. What is meditation? Proposing an empirically derived  
480 classification system. *Frontiers in psychology*. 2019;10:2276.
- 481 11. Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, et al.  
482 Clinical practice guidelines on the evidence-based use of integrative therapies during and after  
483 breast cancer treatment. *CA: a cancer journal for clinicians*. 2017;67(3):194-232.
- 484 12. Horowitz S. Health benefits of meditation: What the newest research shows. *Alternative*  
485 *and Complementary Therapies*. 2010;16(4):223-8.
- 486 13. Huberty J, Eckert R, Larkey L, Joeman L, Mesa R. Experiences of Using a Consumer-  
487 Based Mobile Meditation App to Improve Fatigue in Myeloproliferative Patients: Qualitative  
488 Study. *JMIR Cancer*. 2019;5(2):e14292.
- 489 14. Huberty J, Puzia M, Eckert R, Larkey L. Cancer patients' and survivors' perceptions of  
490 the calm app: cross-sectional descriptive study. *JMIR cancer*. 2020;6(1):e16926.
- 491 15. Puzia ME, Huberty J, Eckert R, Larkey L, Mesa R. Associations between global mental  
492 health and response to an app-based meditation intervention in myeloproliferative neoplasm  
493 patients. *Integrative cancer therapies*. 2020;19:1534735420927780.
- 494 16. Russell L, Ugalde A, Livingston PM, Orellana L, Milne D, Krishnasamy M, et al. A pilot  
495 randomised controlled trial of an online mindfulness-based program for people diagnosed with  
496 melanoma. *Supportive Care in Cancer*. 2019;27(7):2735-46.
- 497 17. Swainston J, Derakshan N. Reduced anxiety following mindfulness and adaptive working  
498 memory training in women with breast cancer. *Mindfulness*. 2021;12(8):1928-39.

- 499 18. Gowin K, Millstine D, Kosiorek HE, Langlais B, Huberty J, Eckert R. The SIMM study:  
500 survey of integrative medicine in myeloproliferative neoplasms. *Haematologica*. 2017;4:102-92.
- 501 19. Kubo A, Altschuler A, Kurtovich E, Hendlish S, Laurent CA, Kolevska T, et al. A pilot  
502 mobile-based mindfulness intervention for cancer patients and their informal caregivers.  
503 *Mindfulness*. 2018;9:1885-94.
- 504 20. Zernicke KA, Campbell TS, Specia M, Ruff KM, Flowers S, Tamagawa R, et al. The  
505 eCALM trial: eTherapy for cancer applying mindfulness. exploratory analyses of the  
506 associations between online mindfulness-based cancer recovery participation and changes in  
507 mood, stress symptoms, mindfulness, posttraumatic growth, and spirituality. *Mindfulness*.  
508 2016;7:1071-81.
- 509 21. Raghunathan NJ, Korenstein D, Li QS, Tonorezos ES, Mao JJ. Determinants of mobile  
510 technology use and smartphone application interest in cancer patients. *Cancer medicine*.  
511 2018;7(11):5812-9.
- 512 22. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, et al. Being  
513 present: a single-arm feasibility study of audio-based mindfulness meditation for colorectal  
514 cancer patients and caregivers. *PLoS One*. 2018;13(7):e0199423.
- 515 23. Huberty J, Bhuiyan N, Puzia M, Joeman L, Larkey L, Mesa R. Meditation Mobile App  
516 Developed for Patients With and Survivors of Cancer: Feasibility Randomized Controlled Trial.  
517 *JMIR cancer*. 2022;8(4):e39228.
- 518 24. Mikolasek M, Witt CM, Barth J. Effects and implementation of a mindfulness and  
519 relaxation app for patients with cancer: Mixed methods feasibility study. *JMIR cancer*.  
520 2021;7(1):e16785.
- 521 25. Kubo A, Kurtovich E, McGinnis M, Aghaee S, Altschuler A, Quesenberry Jr C, et al. A  
522 randomized controlled trial of mHealth mindfulness intervention for cancer patients and informal  
523 cancer caregivers: a feasibility study within an integrated health care delivery system. *Integrative*  
524 *cancer therapies*. 2019;18:1534735419850634.
- 525 26. Huberty J, Bhuiyan N, Neher T, Joeman L, Mesa R, Larkey L. Leveraging a Consumer-  
526 Based Product to Develop a Cancer-Specific Mobile Meditation App: Prototype Development  
527 Study. *JMIR Formative Research*. 2022;6(1):e32458.
- 528 27. Russell L, Orellana L, Ugalde A, Milne D, Krishnasamy M, Chambers R, et al. Exploring  
529 Knowledge, Attitudes, and Practice Associated With Meditation Among Patients With  
530 Melanoma. *Integrative Cancer Therapies*. 2018;17(2):237-47.
- 531 28. Kripalani S, Bengtzen R, Henderson LE, Jacobson TA. Clinical research in low-literacy  
532 populations: using teach-back to assess comprehension of informed consent and privacy  
533 information. *IRB: Ethics & Human Research*. 2008;30(2):13-9.
- 534 29. Robinson J. Using focus groups. *Handbook of qualitative research in education*: Edward  
535 Elgar Publishing; 2020. p. 338-48.
- 536 30. Woźniak W. Homogeneity of Focus Groups as a Pathway to Successful Research  
537 Findings? *Przegląd Socjologii Jakościowej*. 2014;10(1):6-23.
- 538 31. Cohen S. Perceived stress in a probability sample of the United States. 1988.
- 539 32. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized  
540 anxiety disorder: the GAD-7. *Archives of internal medicine*. 2006;166(10):1092-7.
- 541 33. Feldman G, Hayes A, Kumar S, Greeson J, Laurenceau J-P. Mindfulness and emotion  
542 regulation: The development and initial validation of the Cognitive and Affective Mindfulness  
543 Scale-Revised (CAMS-R). *Journal of psychopathology and Behavioral Assessment*.  
544 2007;29:177-90.

- 545 34. Hunt CA, Hoffman MA, Mohr JJ, Williams A-l. Assessing perceived barriers to  
546 meditation: The determinants of meditation practice inventory-revised (DMPI-R). *Mindfulness*.  
547 2020;11:1139-49.
- 548 35. Williams A-l, Dixon J, McCorkle R, Van Ness PH. Determinants of meditation practice  
549 inventory: development, content validation, and initial psychometric testing. *Alternative*  
550 *Therapies in Health and Medicine*. 2011;17(5):16.
- 551 36. Gill P, Stewart K, Treasure E, Chadwick B. Methods of data collection in qualitative  
552 research: interviews and focus groups. *British dental journal*. 2008;204(6):291-5.
- 553 37. Plummer-D'Amato P. Focus group methodology Part 1: Considerations for design.  
554 *International Journal of Therapy and Rehabilitation*. 2008;15(2):69-73.
- 555 38. Guest G, Namey E, McKenna K. How many focus groups are enough? Building an  
556 evidence base for nonprobability sample sizes. *Field methods*. 2017;29(1):3-22.
- 557 39. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the  
558 number of events per variable in logistic regression analysis. *Journal of clinical epidemiology*.  
559 1996;49(12):1373-9.
- 560 40. Krueger RA. *Focus groups: A practical guide for applied research*: Sage publications;  
561 2014.
- 562 41. Onwuegbuzie AJ, Dickinson WB, Leech NL, Zoran AG. A qualitative framework for  
563 collecting and analyzing data in focus group research. *International journal of qualitative*  
564 *methods*. 2009;8(3):1-21.
- 565 42. Martínez-Pérez B, De La Torre-Díez I, López-Coronado M. Mobile health applications  
566 for the most prevalent conditions by the World Health Organization: review and analysis. *Journal*  
567 *of medical Internet research*. 2013;15(6):e120.
- 568 43. Zheng C, Chen X, Weng L, Guo L, Xu H, Lin M, et al. Benefits of Mobile Apps for  
569 Cancer Pain Management: Systematic Review. *JMIR mHealth and uHealth*. 2020;8(1):e17055.
- 570 44. Hughes R, Huby M. The application of vignettes in social and nursing research. *Journal*  
571 *of advanced nursing*. 2002;37(4):382-6.
- 572 45. Mao JJ, Ismaila N, Bao T, Barton D, Ben-Arye E, Garland EL, et al. Integrative medicine  
573 for pain management in oncology: society for integrative oncology–ASCO guideline. *Journal of*  
574 *Clinical Oncology*. 2022;40(34):3998-4024.
- 575  
576